Svb Leerink Equities Analysts Increase Earnings Estimates for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) – Analysts at Svb Leerink lifted their FY2020 earnings estimates for shares of Alexion Pharmaceuticals in a research note issued on Tuesday, July 16th. Svb Leerink analyst now forecasts that the biopharmaceutical company will post earnings per share of $11.35 for the year, up from their prior forecast of $11.30.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.40. The firm had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.13 billion. Alexion Pharmaceuticals had a net margin of 9.59% and a return on equity of 19.53%. Alexion Pharmaceuticals’s revenue was up 22.5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.68 earnings per share.

Other research analysts have also recently issued reports about the stock. Royal Bank of Canada reduced their price target on shares of Gildan Activewear from $34.00 to $33.00 and set a “sector perform” rating on the stock in a research report on Wednesday, March 27th. BidaskClub lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 9th. Goldman Sachs Group upgraded shares of Lenovo Group from a “neutral” rating to a “buy” rating in a research note on Thursday, May 23rd. They noted that the move was a valuation call. ValuEngine upgraded shares of Zuora from a “hold” rating to a “buy” rating in a research note on Saturday, July 6th. Finally, TheStreet lowered shares of Trinity Industries from a “b” rating to a “c” rating in a research note on Thursday, April 25th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and thirteen have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $161.06.

Shares of ALXN stock opened at $123.26 on Wednesday. The firm has a market capitalization of $27.54 billion, a PE ratio of 17.39, a price-to-earnings-growth ratio of 0.92 and a beta of 1.64. The company has a current ratio of 3.87, a quick ratio of 3.36 and a debt-to-equity ratio of 0.25. Alexion Pharmaceuticals has a fifty-two week low of $92.56 and a fifty-two week high of $141.86. The firm’s 50 day simple moving average is $123.54.

In related news, Director Bros. Advisors Lp Baker sold 300,000 shares of Alexion Pharmaceuticals stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $123.74, for a total value of $37,122,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Indrani Lall Franchini sold 4,500 shares of Alexion Pharmaceuticals stock in a transaction on Monday, July 1st. The stock was sold at an average price of $132.78, for a total transaction of $597,510.00. Following the completion of the sale, the executive vice president now owns 29,627 shares of the company’s stock, valued at approximately $3,933,873.06. The disclosure for this sale can be found here. Insiders have sold 428,567 shares of company stock worth $53,420,869 in the last quarter. Insiders own 4.08% of the company’s stock.

Large investors have recently modified their holdings of the stock. Vigilant Capital Management LLC increased its stake in Alexion Pharmaceuticals by 4.1% during the second quarter. Vigilant Capital Management LLC now owns 113,829 shares of the biopharmaceutical company’s stock valued at $14,909,000 after purchasing an additional 4,467 shares during the last quarter. Bank of The West increased its stake in Alexion Pharmaceuticals by 4.1% during the second quarter. Bank of The West now owns 34,841 shares of the biopharmaceutical company’s stock valued at $4,563,000 after purchasing an additional 1,384 shares during the last quarter. Oakbrook Investments LLC bought a new stake in Alexion Pharmaceuticals during the second quarter valued at $1,601,000. Fox Run Management L.L.C. bought a new stake in Alexion Pharmaceuticals during the second quarter valued at $604,000. Finally, NEXT Financial Group Inc bought a new stake in Alexion Pharmaceuticals during the second quarter valued at $36,000. Institutional investors and hedge funds own 94.74% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Recommended Story: Hedge Funds Explained

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit